Role of antimicrobial peptides in inflammatory bowel disease

Polymers

Volumn 3, Issue 4, 2011, Pages 2010-2017

  Otte, Jan Michel ^a   Vordenbäumen, Stefan ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cathelicidin; Defensin; Inflammatory bowel disease

Indexed keywords

ADAPTIVE IMMUNE RESPONSE; ANTI-MICROBIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; CATHELICIDIN; CROHN'S DISEASE; DEFENSINS; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS;

DISEASES;

POLYPEPTIDES;

EID: 84861789002     PISSN: None     EISSN: 20734360     Source Type: Journal    
DOI: 10.3390/polym3042010     Document Type: Review

References (34)

1. Podolsky, D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347, 417-429.
2. Xavier, R.J.; Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448, 427-434.
3. Sartor, R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126, 1620-1633.
4. Cunliffe, R.N.; Mahida, Y.R. Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J. Leukocte Biol. 2004, 75, 49-58.
5. Gosh, D.; Porter, E.; Shen, B.; Lee, S.K.; Wilk, D.; Drazba, J.; Yaday, S.P.; Crabb, J.W.; Ganz, T.; Bevins, C.L. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat. Immunol. 2002, 3, 583-590.
6. Sallenave, J.M. Secretory leukocyte protease inhibitor and elafin/trappin-2: Versatile mucosal antimicrobials and regulators of immunity. Am. J. Respir. Cell. Mol. Biol. 2010, 42, 635-643.
7. Kotarsky, K.; Sitnik, K.M.; Stenstad, H.; Kotarsky, H.; Schmidtchen, A.; Koslowski, M.; Wehkamp, J.; Agace, W.W. A novel role for constitutively expressed epithelial-derived chemokines as antibacterial peptides in the intestinal mucosa. Mucosal. Immunol. 2010, 3, 40-48.
8. Canny, G.; Cario, E.; Lennartsson, A.; Gullberg, U.; Brennan, C.; Levy, O.; Colgan, S.P. Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am. J. Physiol. Gastrointest. Liver. Physiol. 2006, 290, G557-G567.
9. Territo, M.C.; Ganz, T.; Selsted, M.E.; Lehrer, R. Monocyte-chemotactic activity of defensins from human neutrohils. J. Clin. Invest. 1989, 84, 2017-2020.
10. Yang, D.; Chen, Q.; Chertov, O.; Oppenheim, J.J. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukocyte Biol. 2000, 68, 9-14.
11. Garcia, J.R.; Jaumann, F.; Schulz, S.; Krause, A.; Rodriguez-Jiminez, J.; Forssmann, U.; Adermann, K.; Klüver, E.; Vogelmeier, C.; Becker, D.; Hedrich, R.; Forssmann, W.G.; Bals, R. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 2001, 306, 257-264.
12. Garcia, J.R.; Krause, A.; Schulz, S.; Rodriguez-Jiminez, J.; Klüver, E.; Adermann, K.; Forssmann, U.; Frimpong-Boateng, A.; Bals, R.; Forssmann, W.G. Human beta-defensin 4: A novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 2001, 15, 1819-1821.
13. Otte, J.-M.; Zdebik, A.E.; Brand, S.; Chromik, A.M.; Strauss, S.; Schmitz, F.; Steinstraesser, L.; Schmidt, W.E. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul. Pept. 2009, 156, 104-117.
14. Diamond, G.; Beckloff, N.; Weinberg, A.; Kisich, K.O. The role of antimicrobial peptides in innate host defense. Curr. Pharm. Des. 2009, 15, 2377-2392.
15. Funderburg, N.; Lederman, M.M.; Feng, Z.; Drage, M.G.; Jadlowsky, J.; Harding, C.V.; Weinberg, A.; Sieg, S.F. Human β-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc. Natl. Acad. Sci. USA 2007, 104, 18631-18635.
16. Baroni, A.; Donnarumma, G.; Paoletti, I.; Longanesi-Cattani, I.; Bifulco, K.; Tufano, M.A.; Carriero, M.V. Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides 2009, 30, 267-272.
17. Chavakis, T.; Cines, D.B.; Rhee, J.S.; Liang, O.D.; Schubert, U.; Hammes, H.P.; Higazi, A.A.; Nawroth, P.P.; Preissner, K.T.; Bdeir, K. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): A link between inflammation and angiogenesis. FASEB J. 2004, 18, 1306-1308.
18. Vetrano, S.; Rescigno, M.; Cera, M.R.; Correale, C.; Rumino, C.; Doni, A.; Fantini, M.; Sturm, A.; Borroni, E.; Repici, A.; Locati, M.; Malesci, A.; Dejana, E.; Danese, S. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 2008, 135, 173-184.
19. Zeissig, S.; Bürgel, N.; Günzel, D.; Richter, J.; Mankertz, J.; Wahnschaffe, U.; Kroesen, A.J.; Zeitz, M.; Fromm, M.; Schultze, J.D. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007, 56, 61-72.
20. Wehkamp, J.; Salzman, A.; Porter, E.; Nuding, S.; Weichenthal, M.; Petras, R.E.; Shen, B.; Schaeffeler, E.; Schwab, M.; Linzmeier, R.; Feathers, R.W.; Chu, H.; Lima, H.J.; Fellermann, K.; Ganz, T.; Stange, E.F.; Bevins, C.L. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. USA 2005, 102, 18129-18134.
21. Salzman, N.H.; Hung, K.; Haribhai, D.; Chu, H.; Karlsson-Sjöberg, J.; Amir, E.; Teggatz, P.; Barman, M.; Hayward, M.; Eastwood, D.; Stoel, M.; Zhou, Y.; Sodergren, E.; Weinstock, G.M.; Bevins, C.L.; Williams, C.B.; Bos, N.A. Enteric defensins are essential regulators of intestinal microbial ecology. Nat. Immunol. 2010, 11, 76-83.
22. Nuding, S.; Fellermann, K.; Wehkamp, J.; Stange, E.F. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007, 56, 1240-1247.
23. Wehkamp, J.; Wang, G.; Kübler, I.; Nuding, S.; Gregorieff, A.; Schnabel, A.; Kays, R.J.; Fellermann, K.; Burk, O.; Schwab, M.; Clevers, H.; Bevins, C.L.; Stange, D.E. The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J. Immunol. 2007, 179, 3109-3118.
24. van Es, J.H.; Jay, P.; Gregorieff, A.; van Gijn, M.E.; Jonkheer, S.; Hatzis, P.; Thiele, A.; van den Born, M.; Begthel, H.; Brabletz, T.; Taketo, M.M.; Clevers, H. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat. Cell Biol. 2005, 7, 381-386.
25. Koslowski, M.J.; Kübler, I.; Chamaillard, M.; Schaeffeler, E.; Reinisch, W.; Wang, G.; Beisner, J.; Teml, A.; Peyrin-Biroulet, L.; Winter, S.; Herrlinger, K.R.; Rutgeerts, P.; Vermeire, S.; Cooney, R.; Fellermann, K.; Jewell, D.; Bevins, C.L.; Schwab, M.; Stange, E.F.; Wehkamp, J. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putatice promotor region are associated with small intestinal Crohn's disease. PLoS One 2009, 4, e4496.
26. Mastroianni, J.R.; Ouellette, A.J. Alpha-defensins in enteric innate immunity: Functional Paneth cell alpha-defensins in mouse colonic lumen. J. Biol. Chem. 2009, 284, 27848-27856.
27. Cunliffe, R.N.; Rose, F.R.; Keyte, J.; Abberley, L.; Chan, W.C.; Mahida, Y.R. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 2001, 48, 176-185.
28. Peyrin-Biroulet, L.; Beisner, J.; Wang, G.; Nuding, S.; Oommen, S.T.; Kelly, D.; Parmentier-Decrucq, R.; Dessein, R.; Merour, E.; Chavatte, P.; Grandjean, T.; Bressenot, A.; Desreumaux, P.; Colombel, J.F.; Desvergne, B.; Stange, E.F.; Wehkamp, J.; Chamaillard, M. Peroxisome proliferator-activated receptor gamma activation is required for maintainance of innate antimicrobial immunity in the colon. Proc. Natl. Acad. Sci. USA 2010, 107, 8772-8777.
29. Kocsis, A.K.; Lakatos, P.L.; Somogyvári, F.; Fuszek, P.; Papp, J.; Fischer, S.; Szamosi, T.; Lakatos, L.; Kovacs, A.; Hofner, P.; Mándi, Y. Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease. Scand. J. Gastroenterol. 2008, 43, 299-307.
30. Fellermann, K.; Stange, D.E.; Schaeffeler, E.; Schmalzl, H.; Wehkamp, J.; Bevins, C.L.; Reinisch, W.; Teml, A.; Schwab, M.; Lichter, P.; Radlwimmer, B.; Stange, E.F. A chromosome 8 gene cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn's disease of the colon. Am. J. Hum. Genet. 2006, 79, 439-448.
31. Schmid, M.; Fellermann, K.; Fritz, P.; Wiedow, O.; Stange, E.F.; Wehkamp, J. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J. Leukocte Biol. 2007; 81, 907-915.
32. Arijs, I.; De Hertogh, G.; Lemaire, K.; Quintens, R.; van Lommel, L.; van Steen, K.; Leemans, P.; Cleynen, I.; van Assche, G.; Vermeire, S.; Geboes, K.; Schuit, F.; Rutgeerts, P. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 2009, 4, e7984.
33. Schauber, J.; Rieger, D.; Weiler, F.; Wehkamp, J.; Eck, M.; Fellermann, K.; Scheppach, W.; Gallo, R.L.; Stange, E.F. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 2006, 18, 615-621.
34. Simms, L.A.; Doecke, J.D.; Walsh, M.D.; Huang, N.; Fowler, E.V.; Radforf-Smith, G.L. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 2008, 57, 903-910.